Tianjin Lisheng Pharmaceutical Co.,Ltd.
Symbol: 002393.SZ
SHZ
25.45
CNYMarktpreis heute
12.3975
P/E-Verhältnis
7.8104
PEG-Verhältnis
4.64B
MRK Kapital
- 0.01%
DIV Rendite
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393-SZ) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 8384.27 | 2220.2 | 1993.6 | 1651.9 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 371.13 | 231.3 | 200.3 | -31.9 | ||||||||||||||||||
balance-sheet.row.net-receivables | 1996.79 | 321.5 | 427.7 | 461.9 | ||||||||||||||||||
balance-sheet.row.inventory | 779.47 | 176.3 | 199.1 | 228.8 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 449.96 | 100.5 | 4.9 | 13.9 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 11610.5 | 2818.5 | 2625.4 | 2356.4 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 4045.76 | 981.9 | 1029.8 | 1136.7 | ||||||||||||||||||
balance-sheet.row.goodwill | 57.92 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 567.45 | 124.9 | 135.5 | 144.2 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 625.37 | 124.9 | 135.5 | 144.2 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 6115.65 | 1810.6 | 1180.6 | 1531.8 | ||||||||||||||||||
balance-sheet.row.tax-assets | 134.98 | 39.5 | 33.7 | 16.3 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 177.12 | 5.3 | 286.1 | 5.5 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 11098.87 | 2962.1 | 2665.6 | 2834.5 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 22709.37 | 5780.6 | 5291 | 5190.9 | ||||||||||||||||||
balance-sheet.row.account-payables | 331.1 | 84.8 | 146.4 | 90.5 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 228.64 | 59.1 | 39.7 | 28.5 | ||||||||||||||||||
balance-sheet.row.tax-payables | 149.6 | 14.6 | 42.5 | 20.3 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 17.77 | 3.9 | 5.4 | 6.2 | ||||||||||||||||||
Deferred Revenue Non Current | 117.89 | 27.9 | 31.8 | 31.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 741.36 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 1093.6 | 467.4 | 543.9 | 1.4 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 906.67 | 223 | 211.7 | 228 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 17.77 | 3.9 | 5.4 | 6.2 | ||||||||||||||||||
balance-sheet.row.total-liab | 3750.51 | 849.2 | 941.7 | 780.4 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 736.51 | 184.3 | 184 | 182.5 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 5422.19 | 1393.7 | 1126.6 | 1098 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 9405.31 | 1612 | 1328.7 | 1439.4 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 3334.68 | 1713.4 | 1710.1 | 1690.7 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 18898.68 | 4903.4 | 4349.4 | 4410.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 22709.37 | 5780.6 | 5291 | 5190.9 | ||||||||||||||||||
balance-sheet.row.minority-interest | 32.24 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-equity | 18930.92 | 4903.4 | 4349.4 | 4410.5 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 22709.37 | - | - | - | ||||||||||||||||||
Total Investments | 6486.78 | 2041.9 | 1380.9 | 1499.8 | ||||||||||||||||||
balance-sheet.row.total-debt | 246.41 | 63 | 45.1 | 34.7 | ||||||||||||||||||
balance-sheet.row.net-debt | -7705.06 | -1925.9 | -1748.2 | -1617.2 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 374.48 | 361.8 | 93.6 | 122.1 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | -0.02 | 67.3 | 66.1 | 60.2 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | -36.38 | -5.5 | -15.4 | -8.7 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 8.97 | -136.5 | 15.4 | 8.7 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 29.92 | 1.6 | 137.9 | 17.6 | ||||||||||||||||||
cash-flows.row.account-receivables | 17.52 | 17.5 | 25.1 | -19.5 | ||||||||||||||||||
cash-flows.row.inventory | 8.91 | 8.9 | 11.1 | -4.4 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -28.3 | 117 | 50.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 3.49 | 3.5 | -15.4 | -8.7 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | -128.58 | -79.3 | 33.8 | -3.6 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 245.52 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -59.66 | -61.7 | -40.9 | -88.2 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 147.74 | 151.5 | 115.3 | 0.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -580 | -470 | -320 | -70 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 339.7 | 390 | 90 | 82 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 31.53 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -120.69 | 9.9 | -155.6 | -76.1 | ||||||||||||||||||
cash-flows.row.debt-repayment | -22.45 | 0 | -0.1 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -6.29 | -54.7 | -54.7 | -18.2 | ||||||||||||||||||
cash-flows.row.other-financing-activites | -65.85 | 5.9 | 21 | 0 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -143.04 | -48.8 | -33.8 | -18.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 30.37 | 25.1 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | -7.46 | 195.7 | 142 | 102 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 7910.84 | 1989 | 1769.6 | 1627.7 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 7918.29 | 1793.3 | 1627.7 | 1525.7 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 245.52 | 209.5 | 331.4 | 196.3 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -59.66 | -61.7 | -40.9 | -88.2 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 185.86 | 147.8 | 290.5 | 108.1 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1170.61 | 1130.2 | 1146.6 | 1091.9 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 515.47 | 495.6 | 486.3 | 454.5 | ||||||||||||||||||
income-statement-row.row.gross-profit | 655.14 | 634.5 | 660.3 | 637.5 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 103.47 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 24.94 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 314.2 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -29.02 | -13.8 | 108.4 | 96.1 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 564.73 | 521.9 | 576.8 | 591.8 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 1080.2 | 1017.5 | 1063.1 | 1046.3 | ||||||||||||||||||
income-statement-row.row.interest-income | -29.87 | 61.2 | 68.3 | 87.6 | ||||||||||||||||||
income-statement-row.row.interest-expense | 1.54 | 0.9 | 0.9 | 0.3 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 314.2 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 49.9 | 296.6 | -57.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -29.02 | -13.8 | 108.4 | 96.1 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 49.9 | 296.6 | -57.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 1.54 | 0.9 | 0.9 | 0.3 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | -194.14 | 67.3 | 66.1 | 75.8 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | 175.88 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | 370.02 | 112.6 | 175.7 | 136.9 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 419.92 | 409.2 | 118.4 | 137.1 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 57.56 | 58.4 | 24.8 | 15 | ||||||||||||||||||
income-statement-row.row.net-income | 374.48 | 361.8 | 93.6 | 122.1 |
Häufig gestellte Frage
Wie hoch ist die Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) Gesamtvermögen?
Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) Gesamtvermögen ist 5780604152.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 594641936.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.560.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 1.019.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.320.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.316.
Was ist der Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 361827990.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 63035414.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 521915434.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 1952585069.000.